Filing Flows › Ocular Therapeutix (OCUL) › Q1 2026
Ocular Therapeutix (OCUL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Ocular Therapeutix (OCUL) reported revenue of $10.8M for the first quarter 2026 (Q1 2026), +0.8% from a year earlier and -19% from the quarter before. Operating margin was -865.5%, net loss $88.6M (821.6% of revenue).
Ocular Therapeutix, Q1 2026: revenue $10.8M (+0.8% year over year), operating margin -865.5%, net loss $88.6M, operating cash flow −$66.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | -19% | +0.8% |
| Operating profit | −$93.3M | — | — |
| Net earnings | −$88.6M | — | — |
| Operating cash flow | −$66.0M | — | — |
What changed
Revenue was $10.8M in Q1 2026, up 1% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $93.3M, an operating margin of -865.5%. Total costs grew 40% against revenue growth of 1%. The fastest-growing cost line was Research & development (+54%). The quarter ended with a net loss of $88.6M, wider than the previous quarter's $64.7M loss.
Operating cash flow was −$66.0M. Non-cash charges added back $1.3M of depreciation and amortization and $15.6M of share-based compensation. Working capital and other items added $5.8M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$70.7M.
Questions
What was Ocular Therapeutix's revenue in the first quarter 2026?
Ocular Therapeutix (OCUL) reported revenue of $10.8M for the first quarter 2026 (Q1 2026), +0.8% from a year earlier and -19% from the quarter before.
Was Ocular Therapeutix profitable in the first quarter 2026?
Operating loss was $93.3M (-865.5% of revenue) and net loss $88.6M.
Source: Ocular Therapeutix 10-Q on SEC EDGAR.